Background Dietary phosphorus restriction, oral administration of phosphorus binders, and
dialysis are the main strategies to control hyperphosphatemia in patients with stage 5 …

A treatment for hyperphosphatemia would be expected to reduce mortality rates for CKD and
dialysis patients. Although rodent studies have suggested sodium-dependent phosphate …

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance
hemodialysis: Results of the CARE study. Most patients with end-stage renal disease …

A direct effect of calcitriol on the regulation of the secretion of parathyroid hormone (PTH)
has been shown in vitro and in vivo. In patients with renal failure on maintenance …

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance
hemodialysis Hyperphosphatemia in patients with ESRD leads to secondary …

The objective was to investigate the bioavailability and mechanism of calcium absorption of
calcium ascorbate (ASC) and calcium acetate (AC). A series of studies was performed in …

The case of a chronic hemodialysis patient with clay pica who developed profound
hypophosphatemia in the absence of any phosphate-binding medications was reviewed …

Background High levels of serum phosphorus both at baseline and during follow-up are
associated with increased mortality in dialysis patients, and administration of phosphate …

A conventional human pharmacokinetic (PK) in vivo study is often considered as the “gold
standard” to determine bioequivalence (BE) of drug products. However, this BE approach is …

We administered calcium carbonate orally to determine its safety and efficacy in treating
nondialyzed patients with mild to moderate renal failure and secondary …